Home › Cancro ovarico › Louisiana › New Orleans
Studi clinici su Cancro ovarico a New Orleans, LA
12 studi su Cancro ovarico cercano partecipanti presso sedi a New Orleans e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
In reclutamentoFase 3
- Louisiana State University HSC - NO Cancer Center, New Orleans
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
In reclutamentoFase 2/3
- University Medical Center New Orleans, New Orleans
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
In reclutamentoFase 2
- Ochsner Medical Center Jefferson, New Orleans
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
In reclutamentoStudio osservazionale
- Ochsner Clinic Foundation, New Orleans
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
In reclutamentoFase 2
- University Medical Center New Orleans /ID# 274755, New Orleans
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
In reclutamentoFase 3
- Ochsner Clinic Foundation, New Orleans
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
In reclutamentoStudio osservazionale
- Tulane Cancer Center, New Orleans
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
In reclutamento
- Louisiana State University Health Science Center, New Orleans
- University Medical Center New Orleans, New Orleans
- West Jefferson Medical Center, Marrero · a 4 mi di distanza
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
In reclutamentoFase 3
- University Medical Center New Orleans, New Orleans
- Ochsner Baptist Medical Center, New Orleans
- Ochsner Medical Center Jefferson, New Orleans
- e altri 1
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- Louisiana State University Health Sciences Center, New Orleans
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
In reclutamentoFase 3
- LSU Health New Orleans, New Orleans
- University Medical Center New Orleans, New Orleans
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, New Orleans
Studi su Cancro ovarico in altre città
- Houston, TX89 studi
- New York City, NY69 studi
- Boston, MA61 studi
- Los Angeles, CA50 studi
- Nashville, TN49 studi
- Arlington, VA46 studi
- Philadelphia, PA44 studi
- Columbus, OH39 studi
- St. Louis, MO38 studi
- Chicago, IL36 studi
- San Antonio, TX31 studi
- Cleveland, OH30 studi
Altri studi a New Orleans
- Cancro (tutti i tipi)12 studi
- Cancro al seno11 studi
- Cancro alla prostata10 studi
- Cancro dell'endometrio9 studi
- Cancro metastatico9 studi
- Cancro ai polmoni9 studi
- Cancro del polmone non a piccole cellule9 studi
- Malattie cardiovascolari9 studi
- Obesità8 studi
- Malattia epatica steatosica8 studi
- Cancro colorettale8 studi
- Fibrillazione atriale8 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.